PL166035B1 - Sposób wytwarzania koniugatu antygenowego PL - Google Patents

Sposób wytwarzania koniugatu antygenowego PL

Info

Publication number
PL166035B1
PL166035B1 PL90288271A PL28827190A PL166035B1 PL 166035 B1 PL166035 B1 PL 166035B1 PL 90288271 A PL90288271 A PL 90288271A PL 28827190 A PL28827190 A PL 28827190A PL 166035 B1 PL166035 B1 PL 166035B1
Authority
PL
Poland
Prior art keywords
gbmp
polysaccharide
protein
group
antibodies
Prior art date
Application number
PL90288271A
Other languages
English (en)
Polish (pl)
Other versions
PL288271A1 (en
Inventor
Harold J Jennings
Francis Michon
Original Assignee
Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Research Council filed Critical Nat Research Council
Publication of PL288271A1 publication Critical patent/PL288271A1/xx
Publication of PL166035B1 publication Critical patent/PL166035B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PL90288271A 1989-12-14 1990-12-14 Sposób wytwarzania koniugatu antygenowego PL PL166035B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44819589A 1989-12-14 1989-12-14

Publications (2)

Publication Number Publication Date
PL288271A1 PL288271A1 (en) 1991-12-16
PL166035B1 true PL166035B1 (pl) 1995-03-31

Family

ID=23779371

Family Applications (2)

Application Number Title Priority Date Filing Date
PL90288271A PL166035B1 (pl) 1989-12-14 1990-12-14 Sposób wytwarzania koniugatu antygenowego PL
PL90302476A PL166659B1 (pl) 1989-12-14 1990-12-14 Sposób wytwarzania frakcji gamma globuliny zdolnej do biernej ochrony przeciw zapaleniu opon mózgowo-rdzeniowych PL

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL90302476A PL166659B1 (pl) 1989-12-14 1990-12-14 Sposób wytwarzania frakcji gamma globuliny zdolnej do biernej ochrony przeciw zapaleniu opon mózgowo-rdzeniowych PL

Country Status (30)

Country Link
US (3) US5576002A (Direct)
EP (1) EP0504202B1 (Direct)
JP (1) JP2637845B2 (Direct)
KR (1) KR0158436B1 (Direct)
CN (4) CN1049223C (Direct)
AR (1) AR243934A1 (Direct)
AT (1) ATE121947T1 (Direct)
AU (1) AU641715B2 (Direct)
BR (1) BR9007917A (Direct)
CA (1) CA2071811C (Direct)
CZ (1) CZ283530B6 (Direct)
DE (1) DE69019164T2 (Direct)
DK (1) DK0504202T3 (Direct)
ES (1) ES2071288T3 (Direct)
FI (2) FI104539B (Direct)
HR (1) HRP920872A2 (Direct)
HU (2) HU218146B (Direct)
IE (1) IE68414B1 (Direct)
IL (1) IL96676A (Direct)
IN (1) IN171747B (Direct)
NO (2) NO305275B1 (Direct)
NZ (1) NZ236471A (Direct)
PH (1) PH30305A (Direct)
PL (2) PL166035B1 (Direct)
RO (1) RO111416B1 (Direct)
RU (1) RU2105568C1 (Direct)
SI (1) SI20008B (Direct)
WO (1) WO1991008772A1 (Direct)
YU (1) YU24391A (Direct)
ZA (1) ZA9010065B (Direct)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
RU2105568C1 (ru) * 1989-12-14 1998-02-27 Нэшнл Рисерч Каунсл Оф Канада Полисахарид neisseria meningitidis с модифицированной группой b, конъюгированный антиген, вакцина против менингита группы b и способ индукции ответа антител к менингиту группы b
ATE203167T1 (de) * 1992-09-24 2001-08-15 Brigham & Womens Hospital Gruppe b streptococcus typ ii und typ v polysaccharid-protein konjugate als impfstoffe
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
JP4233113B2 (ja) * 1995-06-07 2009-03-04 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
ATE252602T1 (de) 1996-08-27 2003-11-15 Chiron Corp Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
PT939647E (pt) 1996-08-27 2002-04-29 Chiron Corp Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
WO1998058670A1 (en) 1997-06-24 1998-12-30 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
PT1630168E (pt) * 1997-08-27 2011-07-20 Novartis Vaccines & Diagnostic Compostos miméticos moleculares de péptidos de meningococos do serogrupo b
WO1999032653A1 (en) 1997-12-23 1999-07-01 North American Vaccine, Inc. Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines
RU2249463C2 (ru) * 1998-08-19 2005-04-10 Бакстер Хелфкэа С.А. Иммуногенный конъюгат бета-пропионамид-связанного полисахарида с белком, использующийся в качестве вакцины
HUP0103100A3 (en) * 1998-08-19 2005-11-28 Baxter Healthcare Sa Immunogenic betha-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6518037B2 (en) * 1999-11-12 2003-02-11 University Of Iowa Research Foundation Two-component system that controls bacterial membrane synthesis
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
US7534444B2 (en) 2001-04-17 2009-05-19 Novattis Vaccines And Diagnostics, Inc. Molecular mimetics of meningococcal B epitopes which elicit functionally active antibodies
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
BR0308768A (pt) * 2002-03-26 2005-02-15 Chiron Srl Sacarìdeos modificados possuindo estabilidade melhorada em água
CN1684707B (zh) * 2002-05-14 2012-09-05 诺华疫苗和诊断有限公司 用于细菌性脑膜炎的粘膜结合疫苗
RU2359696C2 (ru) * 2002-08-02 2009-06-27 ГлаксоСмитКлайн Байолоджикалз с.а. Вакцинная композиция, содержащая трансферрин-связывающий белок и hsf из грамотрицательных бактерий
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
AU2004227852B2 (en) * 2003-03-31 2010-01-14 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
WO2005016949A2 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
EP1784428A2 (en) * 2004-06-23 2007-05-16 Children's Hospital & Research Center at Oakland Polysaccharide derivatives and uses in induction of an immune response
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
ES2621780T3 (es) 2005-06-27 2017-07-05 Glaxosmithkline Biologicals S.A. Procedimiento de fabricación de vacunas
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP1872791A1 (en) * 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
AU2008265767B2 (en) * 2007-06-20 2014-11-13 Pfizer Ireland Pharmaceuticals Modified polysaccharides for conjugate vaccines
AU2008335457B2 (en) 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
US9050283B2 (en) 2009-01-16 2015-06-09 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal Salmonella
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP2752403A1 (de) * 2013-01-08 2014-07-09 Sika Technology AG Amin für emissionsarme Epoxidharz-Produkte
CN113637040A (zh) 2015-08-19 2021-11-12 哈佛学院院长及董事 脂化psa组合物和方法
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
SG10202111092UA (en) * 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
RU2105568C1 (ru) * 1989-12-14 1998-02-27 Нэшнл Рисерч Каунсл Оф Канада Полисахарид neisseria meningitidis с модифицированной группой b, конъюгированный антиген, вакцина против менингита группы b и способ индукции ответа антител к менингиту группы b

Also Published As

Publication number Publication date
HU9201966D0 (en) 1992-10-28
US5576002A (en) 1996-11-19
FI104539B (fi) 2000-02-29
US5683699A (en) 1997-11-04
ATE121947T1 (de) 1995-05-15
CA2071811A1 (en) 1991-06-15
NO973311L (no) 1992-08-14
NO922316L (no) 1992-08-14
CN1036522C (zh) 1997-11-26
NZ236471A (en) 1992-10-28
FI19991917L (fi) 1999-09-09
FI922737A0 (fi) 1992-06-12
CN1072506C (zh) 2001-10-10
CN1055541A (zh) 1991-10-23
US5902586A (en) 1999-05-11
CN1049223C (zh) 2000-02-09
RO111416B1 (ro) 1996-10-31
HU218146B (hu) 2000-06-28
SI20008A (sl) 2000-02-29
PL166659B1 (pl) 1995-06-30
AR243934A1 (es) 1993-09-30
EP0504202B1 (en) 1995-05-03
CN1036504C (zh) 1997-11-26
HUT64480A (en) 1994-01-28
CN1100428A (zh) 1995-03-22
IL96676A (en) 1996-09-12
ES2071288T3 (es) 1995-06-16
PH30305A (en) 1997-02-20
BR9007917A (pt) 1992-10-20
RU2105568C1 (ru) 1998-02-27
CZ283530B6 (cs) 1998-04-15
NO973311D0 (no) 1997-07-17
SI20008B (en) 2001-02-28
DE69019164T2 (de) 1995-09-07
EP0504202A1 (en) 1992-09-23
JPH05505392A (ja) 1993-08-12
IN171747B (Direct) 1992-12-26
ZA9010065B (en) 1992-02-26
NO307835B1 (no) 2000-06-05
CN1096516A (zh) 1994-12-21
IE904513A1 (en) 1991-06-19
CN1100656A (zh) 1995-03-29
AU641715B2 (en) 1993-09-30
NO305275B1 (no) 1999-05-03
YU24391A (sh) 1995-12-04
IL96676A0 (en) 1991-09-16
PL288271A1 (en) 1991-12-16
FI19991917A7 (fi) 1999-09-09
DK0504202T3 (da) 1995-10-02
HRP920872A2 (en) 1997-06-30
CZ628490A3 (en) 1997-12-17
CA2071811C (en) 2003-11-04
IE68414B1 (en) 1996-06-12
WO1991008772A1 (en) 1991-06-27
KR0158436B1 (ko) 1998-12-01
AU6898791A (en) 1991-07-18
JP2637845B2 (ja) 1997-08-06
DE69019164D1 (de) 1995-06-08
NO922316D0 (no) 1992-06-12

Similar Documents

Publication Publication Date Title
PL166035B1 (pl) Sposób wytwarzania koniugatu antygenowego PL
US5969130A (en) Meningococcal polysaccharide conjugate vaccines
JP2004505885A (ja) Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
MXPA03010283A (es) Conjugados inmunogenicos de acido hialuronico de peso molecular bajo con toxinas de polipeptido.

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20081214